A phase II study of carboplatin plus gemcitabine in advanced non-small- cell lung cancer (NSCLC): A hoosier oncology group study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 6, 1999, Pages 550-553

  Ng, Elizabeth W ^a   Sandler, Alan B ^a   Robinson, Leslie ^b   Einhorn, Lawrence H ^a  

^a INDIANA UNIVERSITY   (United States)

^b Fort Wayne Oncology and Hematology Inc   (United States)

Author keywords

Carboplatin; Gemcitabine; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MORBIDITY; PHASE 2 CLINICAL TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; REMISSION INDUCTION; RIBONUCLEOTIDE REDUCTASES; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 0033512165     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199912000-00003     Document Type: Article

References (27)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics. 1997. CA Cancer J Clin 1997;47:5-27.
2. Ruckdeshel J, Finkelstein D, Ettinger D, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986;4:14-22.
3. Bonomi PD, Finkelstein D, Ruckdeshel J, et al. Combination chemotherapy versus single agents followed by a combination chemotherapy in stage IV non-small cell lung cancer. J Clin Oncol 1989;7:1602-13.
4. Weick J, Crowley J, Natale R, et al. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1991;9:1157-62.
5. Ramanathan RK, Belani CP. Chemotherapy for advanced non-small cell lung cancer: past, present and future. Semin Oncol 1997;24:440-54.
6. Wozniak A, Crowley JJ, Balerzak SP, et al. Randomized phase III trial of cisplatin (CDDP) vs CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): report of a Southwest Oncology Group study [Abstract]. Proc Am Soc Clin Oncol 1996;15:374.
7. Bonomi PD, Kim K, Chang A, et al. Phase III trial comparing etoposide plus cisplatin versus taxol with cisplatin-G-CSF versus cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group trial [Abstract]. Proc Am Soc Clin Oncol 1996;15:382.
8. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′2′-difluoro-2′-deoxycytidine). Cancer Res 1990;50:4417-22.
9. Gatzmeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer. Eur J Cancer 1996;32:243-8.
10. Negoro S, Fukuoka M, Kurita Y, et al. Results of phase II trials of gemcitabine on non-small cell lung cancer [Abstract]. Proc Am Soc Clin Oncol 1994;13:367.
11. Anderson H, Thatcher N, Walling J, et al. Gemcitabine and palliation of symptoms in non-small cell lung cancer [Abstract]. Proc Am Soc Clin Oncol 1994;13:367.
12. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small cell lung cancer. J Clin Oncol 1994;12:1535-40.
13. Peter GJ, Bergman AM, Ruiz van Haperen VWT, et al. Schedule dependency of the synergism between cisplatin and gemcitabine in resistant A2780 human ovarian cancer cell lines [Abstract]. Ann Oncol 1994;5:82.
14. Braakhuis BJ, Ruiz van Haperen VWT, Bergman AM, et al. Preclinical in vivo evaluation of the combination of 2′,2′-difluorodeoxycytidine (gemcitabine) and cisplatin [Abstract]. Ann Oncol 1994;5:82.
15. Sandler AB, Nguyen B, Ansari R, et al. A phase II study of gemcitabine and cisplatin in patients with non-small cell lung cancer. Cancer Therapeutics 1998;1:158-63.
16. Steward WP, Dunlop DJ, Cameron C, et al. Phase I/II study of cisplatin in combination with gemcitabine in non-small cell lung cancer [Abstract]. Proc Am Soc Clin Oncol 1995;14:351.
17. Crino L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer. A phase II study. J Clin Oncol 1997;15:297-303.
18. Abratt RP, Bezwoda WR, Goedhals L, et al. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 1997;15:744-9.
19. Anton A, Carrato A, Gonzalez Larriba JL, et al. Phase II activity of gemcitabine in combination with cisplatin in advanced non-small cell lung cancer [Abstract], Proc Am Soc Clin Oncol 1996; 15:380.
20. Shepherd F, Cormier Y, Evans W, et al. Phase II study of gemcitabine and cisplatin weekly × 3 every 4 weeks in patients with non-small cell lung cancer [Abstract]. Proc Am Soc Clin Oncol 1996;15:380.
21. Johnson DH, Einhorn LH. Paclitaxel plus carboplatin: an effective combination chemotherapy for advanced non-small cell lung cancer or just another Elvis sighting? [Editorial]. J Clin Oncol 1995; 13:1840-2.
22. Carmichael J, Allerheiligen S, Walling J, A phase I/II study of gemcitabine and carboplatin in NSCLC [Abstract], Proc Am Soc Clin Oncol 1995;14:351.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
24. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-70.
25. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 1996;14:2054-60.
26. Vafai D, Israel V, Zaretsky S. Phase I/II trial of combination carboplatin and taxol in non-small cell lung cancer (NSCLC) [Abstract]. Proc Am Soc Clin Oncol 1995;14:352.
27. Kearns CM, Belani CP, Erkman M, et al. Reduced platelet toxicity with combination carboplatin and paclitaxel: pharmacodynamic modulation of carboplatin associated thrombocytopenia [Abstract], Proc Am Soc Clin Oncol 1995;14:170.